Question 1

What’s the financial overview for Catalyst Pharmaceuticals, Inc.?

Accepted Answer

Catalyst Pharmaceuticals, Inc.’s market cap stands at $0.003 trillion right now. The company’s trailing twelve-month earnings per share EPS is $1.57, with a dividend yield of N/A%. Their next earnings report is set for January 29, 2025, and the estimated EPS for that period is $1.61. You can also check out summaries of their income statement, balance sheet, and cash flow details for a fuller picture of their financials.

Question 2

How can I analyze historical data?

Accepted Answer

To analyze historical data with AI tools, apply the date range filter above the table to focus on a specific period. The table displays daily open, high, low, close prices, and volume, enabling you to spot trends and patterns. Use these insights to make informed decisions based on historical performance.

Question 3

What does Catalyst Pharmaceuticals, Inc. Stock ROE tell us?

Accepted Answer

Catalyst Pharmaceuticals, Inc. stock ROE shows positive market sentiment. A higher ROE means the company’s management is doing a better job at using equity financing to drive income and growth. It’s a handy metric for comparing how a company stacks up against its competitors or the broader market.

Question 4

What do Analysts say about Catalyst Pharmaceuticals, Inc.?

Accepted Answer

3 number of Analysts recommended buying Catalyst Pharmaceuticals, Inc. the stock and 0 analysts recommended selling the stock.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024
Revenue	$141.82M	$128.69M	$122.71M	$98.51M
Cost of Revenue	$21.64M	$19.28M	$24.75M	$12.52M
Gross Profit	$120.18M	$109.42M	$97.96M	$85.99M
Gross Profit Ratio	$0.85	$0.85	$0.80	$0.87
R&D Expenses	$3.80M	$3.28M	$2.98M	$2.58M
SG&A Expenses	$44.19M	$45.88M	$40.73M	$46.94M
Operating Expenses	$57.33M	$58.51M	$43.72M	$58.86M
Total Costs & Expenses	$78.98M	$77.79M	$68.46M	$71.38M
Interest Income	$0.00	$0.00	$0.00	$0.00
Interest Expense	$0.00	$0.00	$0.00	$0.00
Depreciation & Amortization	$9.53M	$0.00	$9.50M	$9.50M
EBITDA	$72.30M	$50.91M	$54.25M	$36.56M
EBITDA Ratio	$0.51	$0.40	$0.44	$0.37
Operating Income	$62.84M	$50.91M	$54.25M	$27.13M
Operating Income Ratio	$0.44	$0.40	$0.44	$0.28
Other Income/Expenses (Net)	$11.34M	$6.30M	$1.54M	$1.96M
Income Before Tax	$74.18M	$57.20M	$55.79M	$29.09M
Income Before Tax Ratio	$0.52	$0.44	$0.45	$0.30
Income Tax Expense	$18.25M	$13.32M	$14.99M	$5.81M
Net Income	$55.94M	$43.88M	$40.79M	$23.27M
Net Income Ratio	$0.39	$0.34	$0.33	$0.24
EPS	$0.47	$0.37	$0.35	$0.20
Diluted EPS	$0.44	$0.35	$0.33	$0.19
Weighted Avg Shares Outstanding	$119.89M	$118.93M	$118.18M	$116.81M
Weighted Avg Shares Outstanding (Diluted)	$126.28M	$125.41M	$124.66M	$123.40M

Catalyst Pharmaceuticals, Inc.